Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

FDA Clears Drug for Urea Cycle Disorders

Glycerol phenylbutyrate has been approved for chronic management of some urea cycle disorders in patients aged 2 years and older. FDA Approvals

Ravicti OK'd for Lethal Urea Cycle Defects

(MedPage Today) -- The Food and Drug Administration has approved glycerol phenylbutyrate (Ravicti) for the treatment of the rare hereditary conditions known as urea cycle disorders.

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

Polycystic kidney disease: An early urea-selective urine-concentrating defect in ADPKD

A defect in urine-concentrating ability is discernable in patients with autosomal dominant polycystic kidney disease (ADPKD) before any decline in glomerular filtration rate, and is associated with el...

A Urea Based Cream for Severe Xerosis in T2DM Patients

Moisturization of foot skin in diabetics is important to prevent diabetic foot complications. This study evaluated the efficacy of a topical urea-based cream compared with a simple emollient. BMC De...

Ravicti approved for urea cycle disorders

(HealthDay)—Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

FDA approves new drug for the chronic management of some urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

FDA Approves Ravicti for the Chronic Management of Some Urea Cycle Disorders

February 1, 2013 -- The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and o...

Efficacy of topical hydrating and emollient lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin Rx 10) in the treatment of skin xerosis and pruritus in hemodialyzed patients: an open prospective pilot trial.

Dry skin and pruritus are common complication of end-stage renal diseases (ESRD), affecting up to 80% of dialysis patients. They are chronic, unpleasant skin manifestations with a strong negative impa...

Effect of a new moisturizing lotion on immediate and cumulative skin hydration: Two randomized, intra-individual, vehicle- and comparator-controlled studies.

Abstract Moisturizers increase skin hydration and can serve as adjunctive care in dermatologic conditions such as xerosis, psoriasis vulgaris, atopic dermatitis and ichthyosis, in which dry skin is im...

Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study.

Background  Although moisturizer usage has been considered a mainstay of treatment for atopic dermatitis (AD) patients, few clinical studies have been investigated. Recently, moisturizers containing...

UT-B1 Mediates Transepithelial Urea Flux in the Rat Gastrointestinal Tract.

The process of urea nitrogen salvaging plays a vital role in the symbiotic relationship between mammals and their intestinal bacteria. The first step in this process requires the movement of urea from...

UreA, the major urea/H(+) symporter in Aspergillus nidulans.

We report here the characterization of UreA, a high-affinity urea/H(+) symporter of Aspergillus nidulans. The deletion of the encoding gene abolishes urea transport at low substrate concentrations, su...